IncellDx, Inc.
Corporate brand
UnclaimedIncellDx is a single-cell diagnostics company developing multiplex RNA and protein detection platforms for precision medicine, oncology, and chronic inflammatory diseases such as Long Covid.
Last updated September 28, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
IncellDx, Inc. is a privately held single-cell diagnostics company headquartered in Hayward, California, United States. The company describes itself as committed to advancing precision medicine by offering transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables simultaneous cell classification and single-cell analysis of proteomic and genomic biomarkers. Its core technologies include multiplex RNA in situ hybridization, multiplex protein detection, and DNA/cell cycle analysis, all performed simultaneously in every cell. IncellDx offers a portfolio of research-use-only (RUO), analyte-specific reagent (ASR), general-purpose reagent (GPR), CE-IVD, and US-IVD products. Notable offerings include the HPV OncoTect 3Dx test, HPV E6/E7 mRNA probes, CMV mRNA probes, hybridization core reagents, cell cycle dye reagents, anti-PD-L1 and anti-CD45 antibodies, and the incellPREP and incellMAX sample preparation product lines. Effective June 7, 2024, all IncellDX product, quality, and policy documents are made available through the HealthBio website. Beyond diagnostics, the company has expanded into therapeutic development for chronic inflammatory diseases. Under the HealthBio banner, its team is pursuing the diagnosis and treatment of conditions starting with Long Covid. The FDA granted HealthBio approval to proceed with a clinical trial in January 2024; this double-blind, placebo-controlled trial was set to begin patient enrollment for patients suffering from Long Covid symptoms. The combination therapeutic has potential to treat other immune-mediated disorders and diseases such as ME-CFS, chronic Lyme disease, and fibromyalgia. The company is led by founder and CEO Dr. Bruce Patterson. Its executive and clinical leadership includes Stefan Glück, MD, PhD (Senior Vice President, Medical Affairs), Brian Brothen (Chief Commercial Officer), and Ram Yogendra, MD, MPH (Senior Vice President, Clinical Affairs). The team's scientists, doctors, and business leaders are experienced in immunology, inflammation, and oncology.
History
IncellDx, Inc. is a single-cell diagnostics company based in Hayward, California, United States. The company was founded by Dr. Bruce Patterson, who serves as its Chief Executive Officer. IncellDx has developed a technology platform that enables simultaneous cell classification and single-cell analysis of proteomic and genomic biomarkers, with applications in precision medicine, oncology, and immunology. The company's product portfolio includes multiplex RNA in situ hybridization assays, multiplex protein detection reagents, and DNA/cell cycle analysis tools. Its flagship diagnostic offering, HPV OncoTect 3Dx, is designed for the detection of high-risk HPV E6/E7 mRNA. Other products include CMV mRNA probes, hybridization core reagents, cell cycle dye reagents, anti-PD-L1 and anti-CD45 antibodies, and the incellPREP and incellMAX sample preparation lines. These products carry various regulatory statuses, including RUO, ASR, GPR, CE-IVD, and US-IVD. In recent years, IncellDx has expanded its focus to include therapeutic development for chronic inflammatory diseases. Operating under the HealthBio name, the company is pursuing diagnosis and treatment of conditions beginning with Long Covid. In January 2024, the FDA granted HealthBio approval to proceed with a double-blind, placebo-controlled clinical trial for a combination therapeutic aimed at Long Covid symptoms. The company believes this therapeutic has potential to treat other immune-mediated disorders such as ME-CFS, chronic Lyme disease, and fibromyalgia. Effective June 7, 2024, all IncellDX product, quality, and policy documents were made available through the HealthBio website, indicating a consolidation of the company's commercial and informational presence under the HealthBio brand. The company's leadership team includes experts in immunology, inflammation, and oncology, and it maintains a medical advisory board, as well as partnerships with investment/equity firms, public relations firms, and medical/CRO protocol experts.
FDA grants HealthBio approval to proceed with a double-blind, placebo-controlled clinical trial for a Long Covid therapeutic.
All IncellDX product, quality, and policy documents become available on the HealthBio website.
Products and positioning
A single-cell diagnostics company advancing precision medicine through simultaneous cell classification and single-cell analysis of proteomic and genomic biomarkers.
HPV OncoTect 3Dx
A diagnostic test for high-risk HPV E6/E7 mRNA detection.
HPV E6, E7 mRNA Probe
Ready-to-use probe for HPV E6/E7 mRNA, regulatory status ASR.
CMV mRNA Probe
Probe for CMV mRNA, 100 tests, regulatory status RUO.
Hybridization Core Reagents
Core reagents for hybridization, 100 tests, regulatory status GPR.
Cell Cycle Dye Reagent
Reagent for cell cycle analysis, 1 mg, regulatory status GPR.
Anti PD-L1 Antibody
Antibody for PD-L1 detection, 50 tests, regulatory status ASR.
Anti CD45 Antibody
Antibody for CD45 detection.
incellPREP Sample Rack
Sample rack for the incellPREP system.
incellPREP Battery Pack
Battery pack for the incellPREP system.
incellPREP Homogenizer
Homogenizer for sample preparation.
incellMAX C Fixative
Fixative for cell preservation, 1 L, regulatory status GPR.
incellMAX Fix/Permeabilizer
Fixation and permeabilization reagent, 50 uses, regulatory status GPR.
CytoStat triCHROME Reagent
Reagent for cell analysis, 50 tests, regulatory status IVD/CE-IVD.
GPR HPV Control Cells
Control cells for HPV testing, 1.8 mL, regulatory status RUO.
Recent events
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/incelldx-united-states · Editorial policy · How profiles are compiled